CBY1 and chronic myelogenous leukemia, BCR-ABL1 positive: Reportedly, CBY1 is significantly downregulated in patients with chronic granulocytic leukemia, which can be upregulated by relevant inhibitors to induce ERS-associated UPR, which promotes β-cyclin inactivation, leading to apoptosis and cell death to eradicate BCR-ABL1 + hematopoiesis for therapeutic purposes (34).